Losartan Potassium Tablets Recalled Due to Impurity Presence
Golden State Medical Supply Inc. is recalling Losartan Potassium Tablets 25 mg because FDA labs confirmed an impurity above acceptable levels.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe severity score under the rubric for significant potential health risks.
Plain-English summary
Golden State Medical Supply Inc. is recalling 11,668 bottles of Losartan Potassium Tablets USP 25 mg (NDC 60429-316-30). The recall was initiated because FDA laboratory testing confirmed the presence of an impurity, N-Methylnitrosobutyric acid (NMBA), in the finished product at levels above the interim acceptable daily intake.
The affected product was distributed in Illinois, Michigan, Minnesota, Pennsylvania, Tennessee, and Texas. Distribution included two U.S. government accounts and one Veterans Affairs account. No foreign accounts were involved. The specific lot codes are GS017981, GS016958, and GS017341, all with an expiration date of 02/2020.
Consumers and healthcare providers should check their inventory for these specific lot codes and stop using the product if it matches the recalled description. Patients should contact their healthcare provider for alternative treatment options or further instructions.
The recalled product
- Product
- Losartan Potassium Tablets USP 25 mg 30 count bottle NDC 60429-316-30 Rx only GSMS Incorporated
- Manufacturer
- Golden State Medical Supply Inc.
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 11,668
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- GS017981 exp 02/2020
- GS016958 exp 02/2020
- GS017341 exp 02/2020
Distribution
Part of a larger recall action
This product is one of 5 recalled by Golden State Medical Supply Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 5 products in this recall →Related recalls
Same manufacturer · Golden State Medical Supply Inc.
See all →- SevereGolden State Medical Supply Recalls Prasugrel Tablets for Failed Dissolution
FDA (Drugs) · 2026-09-09
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
Same hazard · impurity
See all →- ModerateAjanta Pharma Recalls Fluphenazine Hydrochloride Tablets Due to Impurity Failure
FDA (Drugs) · 2026-09-16
- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
Similar recalls
- SevereLosartan Potassium Tablets Recalled Due to Impurity Detection
FDA (Drugs) · 2019-07-17
- SevereLosartan Potassium Tablets Recalled Due to Nitrosamine Impurity
FDA (Drugs) · 2019-07-17
- SevereLosartan Potassium Tablets Recalled Due to NMBA Impurity Detection
FDA (Drugs) · 2019-07-17
- SevereLosartan Potassium Tablets Recalled Due to NBMA Impurity Detection
FDA (Drugs) · 2020-04-22
- SevereAvKARE Recalls Losartan Potassium Tablets Due to Impurity
FDA (Drugs) · 2019-05-08
- SevereLosartan Potassium Tablets Recalled Due to Impurity Presence
FDA (Drugs) · 2019-03-27